Byotrol Share Discussion Threads

[sikhthetech] 15/11/2020 18:02

Riddleone,

"I think their 11p target 2021 is too low"

Why? It's Byotrol's broker's target price.

The company stated recently that they expect to meet market expectations.
Finncap, their broker, have expectations: revenues for fy2021 at £11.5m and adj ebitda at £1.7m and tp of 11p.
Given we're in the biggest pandemic for 100yrs I would have thought they would be saying that they would significantly beat market expectations, wouldn't you? If there is a vaccine, will they miss those expectations?
Making only £11.5m and only £1.7m adj Ebitda when we have the biggest pandemic in 100yrs, doesn't inspire me with confidence.

Are you saying the company and is wrong in stating they will meet market expectations???

H1 ended 30th Sept. They still haven't published H1 figures.
They say net cash remains strong, how much cash have they got?

They previously stated that trading was at record levels, it's now at healthly levels. That implies reduced trading compared to the £1m per month, record levels, they were trading at 6 months ago.


"The Directors are pleased to report that trading remains at healthy levels, across all business units and product sales.

We expect results for the year to 31 March 2021 to meet current market expectations, notwithstanding the recent news on the development of potential vaccines against Covid-19.
The Group's net cash position remains strong"




Finncap notes - free to register:

rev £11.5m
adj Ebitda £1.7m
tp 11p.

[1gw] 15/11/2020 17:52

I agree the licence fee side is looking strong. I also think it is beginning to look like there might be more than 1 credible path to retail success for byotrol in its own right.

For Actizone the company can hopefully leverage sales and marketing effort put in by Solvay and/or “the FMCG companies and big brands” referred to by Solvay that are looking to take Actizone for their own products, smoothing the way for a byotrol-branded Actizone product.

In the US, very early days still, but the company (through its licensee) can perhaps leverage sales and marketing effort by Turtle Wax, assuming the Turtle Wax product (carrying the “with BYOTROL technology” tag) is essentially byotrol24. While retail success by byotrol24 will manifest itself in licence fee income (at least for the 10 years of the licence agreement), getting the byotrol name well-known in the US market may open up retail possibilities for other products.

And in the UK, success by Boots with its hand sanitizer product (carrying the byotrol brand) should open the door to increased retail sales of Invirtu, although that might benefit from increased prominence of “byotrol”; on the Invirtu packaging.

[best1467] 15/11/2020 16:54

I feel we could well see an explosion in IP royalties over the next 18 months but the more I look into the sector in general I strongly believe this company may well get taken out by a larger player the Ip alone must be worth Multiples of the current MCap

[james188] 13/11/2020 19:38

BYOT is an interesting play, but I really struggle to think that it should trade on the same sort of multiples as TSTL, which is a much more mature business, with a credible roll out international plan. This is not to denigrate BYOT, but I think that it is in an entirely different space to TSTL.

[riddlerone] 13/11/2020 19:15

Thanks football,I think their 11p target 2021 is too low.When you look at Tristel and their valuation I think we should be a multiple of where we are now.2021 has all the signs of being a breakthrough year for Byotrol IMHO

[football] 13/11/2020 18:38

71p Price Target



BYOTROL - Byotrol plc is engaged in the development, patenting, licensing, and sale of anti-microbial products and technologies.
Byotrol (LON:BYOT) Had a year low of 1.5p this year and has already multi-bagger at 6.3p today, but this feels like the start of the beginning for this company.

Today's AGM statement was enough to open a new position. Link to statement hxxps://www.stockopedia.com/sh...

( I opened a new long position today, lowest buy price 6.3p).

Byotrol (LON:BYOT) has come of age for a number of reasons including;

Covid-19 driving the importance of anti-microbial disinfectant for surfaces
New regulation requiring that disinfectants will be for use in hospitals and will conform with the requirements of the European Biocidal Products Registration and the UK equivalent that will come into force post-Brexit. This is taking many older products out of the market. Even well-established players in the market like Tristel (LON:TSTL) are re-engineering products and finding they need Byotrol (LON:BYOT) IP and products. See attached link, Tristel alliance with Byotrol targets hospitals with the novel product, hxxps://www.businessweekly.co....
90% plus sales growth
300% plus EPS growth
Starting to generate positive cash flow and profits.
Sales Estimates FY21-25

588f5f51b6e715f591950ca5b42f0503d37e8c101605269684.png

Evaluation model suggests 11p valuation for year-end 2021, (71p upper-end target for 2026). See the graph below

[riddlerone] 13/11/2020 18:38

Thanks 1gw with that Tristel which is an unknown entity and Solvay's blockbuster the IP licences could pay us a nice dividend in 2021 after today's resolution being passed.

[football] 13/11/2020 18:28

1gw good link and maybe 2021 will be Byotrol's year only if it was in a America's Supermarket



Who are the top 10 Grocers in the United States (2019)
WALMART INC. Grocery Sales: $288 billion from 4,253 stores. ...

[1gw] 13/11/2020 18:08

So here's another Walmart link - this one for the Turtle Wax product with byotrol in it. There's no price, so doesn't appear to be a live product. It also doesn't appear to carry the "Defend-X" trademark.

But something to keep an eye on.

[football] 13/11/2020 13:32

sad git STT spending coins to hide posts again

[football] 13/11/2020 10:45

anyone got the link for the agm?


tia

[rivaldo] 13/11/2020 10:08

Excellent find, cheers. Couldn't BYOT have issued this as an RNSNON? It may not be immediately material, but it's still important to see yet another blue chip name such as Shell collaborating with BYOT.

I liked from today's RNS:

"Demand for IP licensing remains robust, with the team exploring multiple new opportunities both in the UK and internationally."

Also comforting that net cash remains strong, that trading remains in line and that "competitors with weaker performance chemistries continuing to withdraw from our market".

I assume an update from Finncap will show unchanged forecasts for the moment, but there's plenty going on.

[riddlerone] 13/11/2020 08:00

The Directors clearly believe that even as we (hopefully)come out of Covid conditions they will be building on the current revenue figures.I like the way they are highlighting clearly on the IP licensing and if they go down the path that DT indicated in the Investors Meet broadcast then we should see at least a couple of new deals every year all at 100% margin.The resolution in the AGM today to provide a pathway to pay a dividend to me says it all and I also look forward to reading the Q&A from the meeting.

[1gw] 13/11/2020 07:52

Reads to me very much as a holding statement. Good to know that they are on track to meet expectations, but frustrating that they still can't give an estimate of revenue or EBITDA for 1H. The issue with the "meet expectations" statement is what it applies to - is it only to EBITDA, which appears to be their primary metric, or is it also to revenue?

I hope the Q&A response provides a bit more insight.

[2vdm] 13/11/2020 07:26

Re-assuring AGM statement today. I particularly like the penultimate paragraph:

The Directors are pleased to report that trading remains at healthy levels, across all business units and product sales. Demand for IP licensing remains robust, with the team exploring multiple new opportunities both in the UK and internationally.

The Group's net cash position remains strong, enabling us to maintain stock levels to fulfil customer demand or where appropriate re-invest for the growth of the business.

We expect results for the year to 31 March 2021 to meet current market expectations, notwithstanding the recent news on the development of potential vaccines against Covid-19. This is supported by industry trends clearly in evidence before (and now magnified by) Covid-19, all of which continue to favour Byotrol's long-term positioning, notably:

-- businesses and consumers taking increasingly proactive responsibility for protecting individuals against infection risk from viruses and bacteria, so increasing global demand; and

-- competitors with weaker performance chemistries continuing to withdraw from our market in the UK and Europe as new regulations take hold, so reducing the supply of competing products and so multiplying opportunities for Byotrol's future growth.

The Directors remain highly confident in Byotrol's longer term outlook.

[1gw] 12/11/2020 17:06

What chance a TU tomorrow? Friday the thirteenth!

If no TU then we can at least look forward to publication of answers to questions that have been submitted either tomorrow or shortly thereafter.

[the ghost who walks] 11/11/2020 07:07

What is our gearing to Slovay news?

[slicethepie] 10/11/2020 11:05

2102 posts I call that fluff.....what did they do to you?

[football] 10/11/2020 09:18

Looks like the Chinese vaccine had to be pulled in stage 3 trial due to side effectsHttps://www.bbc.co.uk/news/world-asia-china-54883383

[brownson] 10/11/2020 09:17

The market calculates all that to be worth 6.5p. The rest was all fluff

[football] 09/11/2020 17:33

Solvay - revenue stream about to come onlineTristel8 - revenue about to come onlineJohnson and Johnson/NHS - Revenue about to kick inByotrol24 - just gone live in AmericaAnd that's without the seaweed and selling off a section of a company for it development

[brownson] 09/11/2020 15:54

Byotrol's prospects are no different